Safety & Toxicology

Nicole Dale

GLP-1 Obesity Evidence Is Changing Clinical Development

Pharmatica GLP-1 obesity clinical development visual showing metabolic therapy, clinical research, and evidence generation.

GLP-1 obesity clinical evidence is reshaping drug development as efficacy, safety, cardiovascular outcomes, and treatment durability become critical.

Nicole Dale

Liver-Chip Supported Drug Discovery Moves to FDA Qualification

Pharmatica image of a human liver-chip platform used for liver-chip drug discovery and preclinical drug toxicity assessment in a pharmaceutical laboratory.

Liver-chip supported drug discovery is moving closer to regulatory acceptance as Emulate advances FDA ISTAND qualification for human-relevant DILI assessment.

Nicole Dale

The Ethics of Decentralised Clinical Trials

Pharmatica image representing decentralised clinical trials using remote monitoring, digital health technology, and telehealth to connect clinical research participants with investigators.

Ethical obligations in decentralised clinical trials extend beyond consent and privacy. Sponsors must protect safety, scientific validity, equity, and oversight.

Nicole Dale

Nanocarriers Target the Eye for Better Ocular Drug Delivery

Pharmatica image representing ocular drug delivery using nanocarriers to improve therapeutic targeting of the eye and retinal tissues.

Ocular drug delivery faces major biological barriers. Nanocarriers could improve bioavailability, tissue targeting, controlled release, and treatment for difficult eye diseases.

Nicole Dale

Psychedelic Drug Discovery Gets a New Preclinical Framework

Pharmatica detailed rendering of a neuron firing electrical impulses through dendrites and axons in vivid green tones, symbolising neural connectivity and communication in psychedelic drug discovery, neuroplasticity, 5-HT2A receptor pharmacology, CNS drug development, psychoplastogens, and therapeutic neuroscience research.

Find out how psychedelic drug discovery is evolving through receptor pharmacology, behavioural science, and neuroplasticity to develop safer CNS therapeutics.

Nicole Dale

Success for Non-Animal Testing of Preclinical Toxicity?

Pharmatica hyper-realistic image of a human organ-on-chip platform with cultured cells used for non-animal testing in drug discovery in order to determine preclinical toxicity in a pharmaceutical research laboratory.

Can non-animal testing methods be used in preclinical drug discovery? Here is what the evidence is for their accuracy and limits assessing preclinical toxicity.

Nicole Dale

Optimising Preclinical Pharmacology for Oncology NMEs

Oncology researcher performing preclinical pharmacology testing for new molecular entities (NMEs), illustrating oncology drug development, translational research, biomarker discovery, and advanced preclinical model optimisation.

Over 90% of oncology NMEs that succeed in animal studies fail in clinical trials. This analysis examines how to optimise preclinical pharmacology models to improve translational success.

Nicole Dale

FDA 2026 Draft Guidance on Alternatives to Animal Testing

Illustration representing FDA alternatives to animal testing, featuring laboratory research, organ-on-chip technology, genetic science, AI-enabled drug discovery and next-generation pharmaceutical testing methods.

The FDA's March 2026 draft guidance on alternatives to animal testing marks a pivotal shift in preclinical drug development. Here's what pharma R&D teams need to know.